update on tirzepatide White Week 27 Update on Tirzepatide

Impact on NAION A paper published in 2024 in JAMA Ophthalmology created shock waves in the ophthalmic community by showing that subcutaneous semaglutide was associated with a significantly higher risk of developing nonarteritic anterior ischemic optic neuropathy (NAION)

This is also when you should be tracking your progress systematically

[1] [3] The medication works through multiple mechanisms, including stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptyingthe rate at which food leaves the stomach and enters the small intestine

If you want to avoid unknown risks to the infant and your condition allows a delay, schedule treatment for after breastfeeding ends and establish a plan for postpartum follow-up

Additionally, it extends the C-terminal with a sequence of exenatide, and thirdly, it has an attached fatty acid side chain, similar to semaglutide, to prolong its half-life [16]

For people with PCOS or insulin resistance, this can help regulate previously irregular cyclesbut it can also take time for your body to adjust